Skip to content

Opening book details…

Can I read Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study on EtoBox?

Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study by Md Yuzaiful Md Yusof; Jack Arnold; Benazir Saleem; Claire Vandevelde; Shouvik Dass; Sinisa Savic; Edward M Vital; Paul Emery is a Medicine article available to read on EtoBox.

What is Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study about?

Background Concerns have been raised regarding the reduced immunogenicity of vaccines against COVID-19 in patients with autoimmune diseases treated with rituximab. However, the incidence and severity of breakthrough infections in unbiased samples of patients with specific rheumatic and musculoskeletal diseases are largely unknown. We aimed to assess the incidence of breakthrough SARS-CoV-2 infection, compare rates of moderate-to-severe COVID-19 with any severe infection event, and evaluate predictors of moderate-to-severe COVID-19 outcomes in patients treated with rituximab. Methods We did a retrospective cohort study in all rituximab-treated patients with rheumatic and musculoskeletal diseases in a single centre in Leeds, UK between March 1, 2020 (the index date), and April 1, 2022. Adults aged 18 years and older, who fulfilled classification criteria for established rheumatic and musculoskeletal diseases, and received therapy with at least one rituximab infusion between Sept 1, 2019 (6 months before the pandemic in the UK), and April 1, 2022, were eligible for inclusion in the study. SARS-CoV-2 infection was defined by antigen test or PCR. COVID-19 outcomes were categorised as mi

Who reads Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study?

It is typically read by researchers, students, and practitioners in Medicine.

Author
Md Yuzaiful Md Yusof; Jack Arnold; Benazir Saleem; Claire Vandevelde; Shouvik Dass; Sinisa Savic; Edward M Vital; Paul Emery
Publisher
Elsevier BV
Published
2023
Language
EN
Field
Medicine (Health Sciences)

More by Md Yuzaiful Md Yusof; Jack Arnold; Benazir Saleem; Claire Vandevelde; Shouvik Dass; Sinisa Savic; Edward M Vital; Paul Emery

Browse all works by Md Yuzaiful Md Yusof; Jack Arnold; Benazir Saleem; Claire Vandevelde; Shouvik Dass; Sinisa Savic; Edward M Vital; Paul Emery